Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine which dosages of dexmethylphenidate HCl extended-release capsules may represent effective treatment for ADHD in children 6-12 years of age.
The purpose of this study is to determine which dosages of dexmethylphenidate HCl extended-release capsules may represent effective treatment for ADHD in children 6-12 years of age.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dexmethylphenidate HCl extended-release capsules | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of the symptoms by the patient's teacher after 5 weeks of treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| Assessment of the symptoms by the patient's parent after five weeks of treatment. | ||
| Change in severity of the illness assessed by the physician after 5 weeks of treatment | ||
Not provided
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novartis Investigational Site | Mesa | Arizona | 85210 | United States | ||
| Novartis Investigational Site |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Improvement of the illness assessed by the physician after 5 weeks of treatment |
| Safety and tolerability of 5 week's treatment with dexmethylphenidate HCl extended-release capsules in children with Attention-Deficit/Hyperactivity Disorder by assessing the frequency of adverse findings |
| Little Rock |
| Arkansas |
| 72205 |
| United States |
| Novartis Investigational Site | Los Angeles | California | 90095 | United States |
| Novartis Investigational Site | Boulder | Colorado | 80304 | United States |
| Novartis Investigational Site | Maitland | Florida | 32751 | United States |
| Novartis Investigational Site | Orlando | Florida | 32806 | United States |
| Novartis Investigational Site | Stone Mountain | Georgia | 30083 | United States |
| Novartis Investigational Site | Libertyville | Illinois | 60048 | United States |
| Novartis Investigational Site | Overland Park | Kansas | 66211 | United States |
| Novartis Investigational Site | Prairie Village | Kansas | 66206 | United States |
| Novartis Investigational Site | Cambridge | Massachusetts | 02138 | United States |
| Novartis Investigational Site | Las Vegas | Nevada | 89128 | United States |
| Novartis Investigational Site | Piscataway | New Jersey | 08855 | United States |
| Novartis Investigational Site | Toms River | New Jersey | 08755 | United States |
| Novartis Investigational Site | New York | New York | 10029 | United States |
| Novartis Investigational Site | New York | New York | 10032 | United States |
| Novartis Investigational Site | Staten Island | New York | 10305 | United States |
| Novartis Investigational Site | Chapel Hill | North Carolina | 27514 | United States |
| Novartis Investigational Site | Raleigh | North Carolina | 27609 | United States |
| Novartis Investigational Site | Columbus | Ohio | 43205 | United States |
| Novartis Investigational Site | Gresham | Oregon | 97030 | United States |
| Novartis Investigational Site | Philadelphia | Pennsylvania | 19149 | United States |
| Novartis Investigational Site | Jackson | Tennessee | 38305 | United States |
| Novartis Investigational Site | Memphis | Tennessee | 38119 | United States |
| Novartis Investigational Site | Houston | Texas | 77007 | United States |
| ID | Term |
|---|---|
| D001289 | Attention Deficit Disorder with Hyperactivity |
| ID | Term |
|---|---|
| D019958 | Attention Deficit and Disruptive Behavior Disorders |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided